These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21715567)

  • 1. Regression of glioma in rat models by intranasal application of parvovirus h-1.
    Kiprianova I; Thomas N; Ayache A; Fischer M; Leuchs B; Klein M; Rommelaere J; Schlehofer JR
    Clin Cancer Res; 2011 Aug; 17(16):5333-42. PubMed ID: 21715567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
    Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
    Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
    J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
    Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
    Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.
    Lacroix J; Leuchs B; Li J; Hristov G; Deubzer HE; Kulozik AE; Rommelaere J; Schlehofer JR; Witt O
    Int J Cancer; 2010 Sep; 127(5):1230-9. PubMed ID: 20087864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
    Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
    Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
    Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
    Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
    Viruses; 2016 May; 8(5):. PubMed ID: 27213425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
    Akladios C; Aprahamian M
    Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
    Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
    BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing.
    Herrero Y Calle M; Cornelis JJ; Herold-Mende C; Rommelaere J; Schlehofer JR; Geletneky K
    Int J Cancer; 2004 Mar; 109(1):76-84. PubMed ID: 14735471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-faceted mechanism of parvoviral oncosuppression.
    Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
    Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varicella zoster virus infection of malignant glioma cell cultures: a new candidate for oncolytic virotherapy?
    Leske H; Haase R; Restle F; Schichor C; Albrecht V; Vizoso Pinto MG; Tonn JC; Baiker A; Thon N
    Anticancer Res; 2012 Apr; 32(4):1137-44. PubMed ID: 22493342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.